A BILL 
To provide for certain additional requirements with respect 
to patent disclosures. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Biologic Patent Trans-
4
parency Act’’. 
5
SEC. 2. PATENT DISCLOSURE REQUIREMENTS. 
6
(a) IN GENERAL.—Section 351 of the Public Health 
7
Service Act (42 U.S.C. 262) is amended by adding at the 
8
end the following: 
9
02:36 Oct 30, 2019
H4850
2 
•HR 4850 IH
‘‘(o) ADDITIONAL REQUIREMENTS WITH RESPECT 
1
TO PATENTS.— 
2
‘‘(1) APPROVED APPLICATION HOLDER LISTING 
3
REQUIREMENTS.— 
4
‘‘(A) IN GENERAL.—Beginning on the date 
5
of enactment of the Biologic Patent Trans-
6
parency Act, within 30 days of approval of an 
7
application under subsection (a) or (k), the 
8
holder of such approved application shall sub-
9
mit to the Secretary a list of each patent re-
10
quired to be disclosed (as described in para-
11
graph (3)). 
12
‘‘(B) 
PREVIOUSLY
APPROVED
OR
LI-
13
CENSED BIOLOGICAL PRODUCTS.— 
14
‘‘(i) PRODUCTS
APPROVED
UNDER 
15
SECTION
351
OF
THE
PHSA.—Not later 
16
than 30 days after the date of enactment 
17
of the Biologic Patent Transparency Act, 
18
the holder of a biological product license 
19
that was approved under subsection (a) or 
20
(k) before the date of enactment of such 
21
Act shall submit to the Secretary a list of 
22
each patent required to be disclosed (as de-
23
scribed in paragraph (3)). 
24
02:36 Oct 30, 2019
H4850
3 
•HR 4850 IH
‘‘(ii) PRODUCTS
APPROVED
UNDER 
1
SECTION 505 OF THE FFDCA.—Not later 
2
than 30 days after March 23, 2020, the 
3
holder of an approved application for a bio-
4
logical product under section 505 of the 
5
Federal Food, Drug, and Cosmetic Act 
6
that is deemed to be a license for the bio-
7
logical product under this section on 
8
March 23, 2020, shall submit a list of each 
9
patent required to be disclosed (as de-
10
scribed in paragraph (3)). 
11
‘‘(C) UPDATES.—The holder of a biological 
12
product license approved under subsection (a) 
13
or (k) shall submit to the Secretary a list that 
14
includes— 
15
‘‘(i) any patent first required to be 
16
disclosed (as described in paragraph (3)) 
17
after the submission under subparagraph 
18
(A) or (B), as applicable, within 30 days of 
19
the earlier of— 
20
‘‘(I) the date of issuance of such 
21
patent by the United States Patent 
22
and Trademark Office; or 
23
02:36 Oct 30, 2019
H4850
4 
•HR 4850 IH
‘‘(II) the date of approval of a 
1
supplemental application for the bio-
2
logical product; and 
3
‘‘(ii) any patent, or any claim with re-
4
spect to a patent, included on the list pur-
5
suant to this paragraph with respect to the 
6
biological product subsequently determined 
7
to be invalid or unenforceable, within 30 
8
days of a determination of patent inva-
9
lidity. 
10
‘‘(2) PUBLICATION OF INFORMATION.— 
11
‘‘(A) IN GENERAL.—Within 1 year of the 
12
date of enactment of the Biologic Patent Trans-
13
parency Act, the Secretary shall publish and 
14
make available to the public a single, easily 
15
searchable, list that includes— 
16
‘‘(i) the official and proprietary name 
17
of each biological product licensed under 
18
subsection (a) or (k), and of each biological 
19
product application approved under section 
20
505 of the Federal Food, Drug, and Cos-
21
metic Act and deemed to be a license for 
22
the biological product under this section on 
23
March 23, 2020; 
24
02:36 Oct 30, 2019
H4850
5 
•HR 4850 IH
‘‘(ii) with respect to each biological 
1
product described in clause (i), each patent 
2
submitted in accordance with paragraph 
3
(1); 
4
‘‘(iii) the date of licensure and appli-
5
cation number for each such biological 
6
product; 
7
‘‘(iv) the marketing status, dosage 
8
form, route of administration, strength, 
9
and, if applicable, reference product, for 
10
each such biological product; 
11
‘‘(v) the licensure status for each such 
12
biological product, including whether the li-
13
cense at the time of listing is approved, 
14
withdrawn, or revoked; 
15
‘‘(vi) any period of any exclusivity 
16
under subsection (k)(7)(A) or subsection 
17
(k)(7)(B) of this section or section 527 of 
18
the Federal Food, Drug, and Cosmetic 
19
Act, and any extension of such period in 
20
accordance with subsection (m) of this sec-
21
tion with respect to each such biological 
22
product, and the date on which such exclu-
23
sivity expires; 
24
02:36 Oct 30, 2019
H4850
6 
•HR 4850 IH
‘‘(vii) information regarding any de-
1
termination related to biosimilarity or 
2
interchangeability for each such biological 
3
product; and 
4
‘‘(viii) information regarding approved 
5
indications for each such biological prod-
6
uct, in such manner as the Secretary de-
7
termines appropriate. 
8
‘‘(B) UPDATES.—Every 30 days after the 
9
publication of the first list under subparagraph 
10
(A), the Secretary shall revise the list to in-
11
clude— 
12
‘‘(i)(I) each biological product licensed 
13
under subsection (a) or (k) during the 30- 
14
day period; and 
15
‘‘(II) with respect to each biological 
16
product described in subclause (I), the in-
17
formation described in clauses (i) through 
18
(viii) of subparagraph (A); and 
19
‘‘(ii) any updates to information pre-
20
viously published in accordance with sub-
21
paragraph (A). 
22
‘‘(3) PATENTS REQUIRED TO BE DISCLOSED.— 
23
In this section, a ‘patent required to be disclosed’ is 
24
any patent for which the holder of a biological prod-
25
02:36 Oct 30, 2019
H4850
7 
•HR 4850 IH
uct license approved under subsection (a) or (k), or 
1
a biological product application approved under sec-
2
tion 505 of the Federal Food, Drug, and Cosmetic 
3
Act and deemed to be a license for a biological prod-
4
uct under this section on March 23, 2020, believes 
5
a claim of patent infringement could reasonably be 
6
asserted by the holder, or by a patent owner that 
7
has granted an exclusive license to the holder with 
8
respect to the biological product that is the subject 
9
of such license, if a person not licensed by the holder 
10
engaged in the making, using, offering to sell, sell-
11
ing, or importing into the United States of the bio-
12
logical product that is the subject of such license.’’. 
13
(b) 
DISCLOSURE
OF
PATENTS.—Section 
14
351(l)(3)(A)(i) of the Public Health Service Act (42 
15
U.S.C. 262(l)(3)(A)(i)) is amended by inserting ‘‘included 
16
in the list provided by the reference product sponsor under 
17
subsection (o)(1)’’ after ‘‘a list of patents’’. 
18
(c) RESTRICTION ON CLAIMS OF PATENT INFRINGE-
19
MENT.—Section 271(e) of title 35, United States Code, 
20
is amended by adding at the end the following: 
21
‘‘(7) The owner of a patent that should have 
22
been included in the list described in section 
23
351(o)(1) of the Public Health Service Act (42 
24
U.S.C. 262(o)(1)), including any updates required 
25
02:36 Oct 30, 2019
H4850
8 
•HR 4850 IH
under subparagraph (C) of that section, but was not 
1
timely included in such list, may not bring an action 
2
under this section for infringement of the patent.’’. 
3
(d) REGULATIONS.—The Secretary of Health and 
4
Human Services may promulgate regulations to carry out 
5
subsection (o) of section 351 of the Public Health Service 
6
Act (42 U.S.C. 262), as added by subsection (a). 
7
(e) RULE OF CONSTRUCTION.—Nothing in this Act, 
8
including an amendment made by this Act, shall be con-
9
strued to require or allow the Secretary of Health and 
10
Human Services to delay the licensing of a biological prod-
11
uct under section 351 of the Public Health Service Act 
12
(42 U.S.C. 262). 
13
Æ 
02:36 Oct 30, 2019
H4850
